News Sonnet Biotherapeutics

Stocks

SONN

US83548R4020

Delayed Nasdaq 04:00:00 2025-12-02 pm EST			5-day change	1st Jan Change
1.260 ^USD	-59.35%		-.--%	-

Dec. 16	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
Dec. 02	Top Midday Decliners	MT

All News

Mentions Relevance

Dec. 16	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
Dec. 02	Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination	AQ
Dec. 02	Top Midday Decliners	MT
Dec. 02	Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies	RE
Dec. 02	Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc	AQ
Dec. 01	Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index	CI
Nov. 18	Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting	AQ
25-10-15	Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma	AQ
25-10-15	Sonnet BioTherapeutics Holdings, Inc. Collaborates with Spanishos on Non-Clinical Study Using New Alternate Methodologies Based Patient-Derived Tumoroid Platform	CI
25-09-19	Sonnet to Present at the MedInvest Biotech & Pharma Conference	AQ
25-08-13	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
25-08-12	Sonnet Releases Virtual Investor What This Means Segment	AQ
25-08-11	Sonnet Releases Virtual Investor "What This Means" Segment	AQ
25-08-11	Sonnet BioTherapeutics Holdings, Inc. Announces Expansion of Its Clinical Study of Patients with Platinum-Resistant Ovarian Cancer	CI
25-08-04	Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study	MT
25-08-04	Sonnet Biotherapeutics expands trial of SON-1010 with atezolizumab in advanced ovarian cancer	RE
25-08-04	Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	AQ
25-08-04	Sonnet BioTherapeutics Holdings, Inc. Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	CI
25-07-14	Sonnet Biotherapeutics, Inc Announces $888 Million Business Combination with Rorschach I LLC to Create Entity to Be Named Hyperliquid Strategies Inc	CI
25-07-14	Sonnet Biotherapeutics, Inc. announces $888 million business combination to launch a hype cryptocurrency treasury reserve strategy	RE
25-07-14	Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy	AQ
25-07-13	Sonnet BioTherapeutics Holdings, Inc. announced that it has received $5.5 million in funding	CI
25-07-10	Sonnet BioTherapeutics Holdings, Inc. announced that it expects to receive $310.23499 million in funding	CI
25-07-07	Top Premarket Gainers	MT
25-06-29	Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.05 million in funding	CI